Last reviewed · How we verify

Avandia and Amaryl — Competitive Intelligence Brief

Avandia and Amaryl (Avandia and Amaryl) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Thiazolidinedione + Sulfonylurea combination. Area: Diabetes.

phase 3 Thiazolidinedione + Sulfonylurea combination PPAR-γ (rosiglitazone); Sulfonylurea receptor / ATP-sensitive potassium channel (glimepiride) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Avandia and Amaryl (Avandia and Amaryl) — Canadian Heart Research Centre. This combination uses rosiglitazone (Avandia) to increase insulin sensitivity and glimepiride (Amaryl) to stimulate insulin secretion, together lowering blood glucose in type 2 diabetes.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Avandia and Amaryl TARGET Avandia and Amaryl Canadian Heart Research Centre phase 3 Thiazolidinedione + Sulfonylurea combination PPAR-γ (rosiglitazone); Sulfonylurea receptor / ATP-sensitive potassium channel (glimepiride)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Thiazolidinedione + Sulfonylurea combination class)

  1. Canadian Heart Research Centre · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Avandia and Amaryl — Competitive Intelligence Brief. https://druglandscape.com/ci/avandia-and-amaryl. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: